← Back to Screener
Stoke Therapeutics, Inc. Common Stock (STOK)
Price$36.46
Favorite Metrics
Price vs S&P 500 (26W)14.70%
Price vs S&P 500 (4W)1.73%
Market Capitalization$2.20B
All Metrics
P/CF (Annual)48.36x
Book Value / Share (Quarterly)$5.98
P/TBV (Annual)0.97x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)145.85%
Cash Flow / Share (Quarterly)$0.76
Price vs S&P 500 (YTD)13.28%
Net Profit Margin (TTM)-3.73%
EPS (TTM)$-0.13
10-Day Avg Trading Volume0.61M
EPS Excl Extra (TTM)$-0.13
EPS (Annual)$-0.12
ROI (Annual)-1.95%
Net Profit Margin (5Y Avg)-2289.09%
Cash / Share (Quarterly)$4.83
P/E Basic Excl Extra (TTM)46.10x
Revenue Growth QoQ (YoY)-93.80%
ROA (Last FY)-1.65%
Revenue Growth TTM (YoY)404.50%
EBITD / Share (TTM)$-0.32
ROE (5Y Avg)-40.10%
Operating Margin (TTM)-11.16%
Cash Flow / Share (Annual)$0.76
P/B Ratio6.25x
P/B Ratio (Quarterly)5.14x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)11.50x
ROA (TTM)-1.75%
EV / EBITDA (TTM)71.07x
EPS Incl Extra (Annual)$-0.12
Current Ratio (Annual)5.28x
Quick Ratio (Quarterly)5.13x
3-Month Avg Trading Volume0.80M
52-Week Price Return392.99%
EV / Free Cash Flow (Annual)47.21x
P/E Incl Extra (TTM)46.10x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$3.91
P/S Ratio (Annual)11.95x
Asset Turnover (Annual)0.44x
52-Week High$40.22
Operating Margin (5Y Avg)-2353.28%
EPS Excl Extra (Annual)$-0.12
CapEx CAGR (5Y)-8.59%
26-Week Price Return23.45%
Quick Ratio (Annual)5.13x
13-Week Price Return20.34%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.28x
Enterprise Value$2,120.33
Asset Turnover (TTM)0.47x
Book Value / Share Growth (5Y)-5.21%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-3.73%
Cash / Share (Annual)$4.83
3-Month Return Std Dev59.88%
Net Income / Employee (TTM)$-0
ROE (Last FY)-1.95%
EPS Basic Excl Extra (Annual)$-0.12
Receivables Turnover (TTM)37.67x
EV / Free Cash Flow (TTM)47.21x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.13
Receivables Turnover (Annual)34.46x
ROI (TTM)-2.05%
P/S Ratio (TTM)11.95x
Pretax Margin (5Y Avg)-2289.09%
Revenue / Share (Annual)$3.11
Tangible BV / Share (Annual)$4.69
Forward P/E3939.76x
Price vs S&P 500 (52W)357.89%
P/E Ratio (TTM)46.10x
Year-to-Date Return17.42%
5-Day Price Return6.33%
EPS Normalized (Annual)$-0.12
ROA (5Y Avg)-31.13%
Net Profit Margin (Annual)-3.73%
Month-to-Date Return14.47%
Cash Flow / Share (TTM)$-2.37
EBITD / Share (Annual)$-0.32
Operating Margin (Annual)-11.16%
P/CF (TTM)48.36x
ROI (5Y Avg)-40.10%
P/E Excl Extra (TTM)46.10x
EPS Basic Excl Extra (TTM)$-0.13
P/TBV (Quarterly)1.04x
P/B Ratio (Annual)5.14x
Pretax Margin (TTM)-3.73%
Book Value / Share (Annual)$5.98
Price vs S&P 500 (13W)17.48%
Beta1.32x
P/FCF (Annual)49.08x
Revenue / Share (TTM)$3.11
ROE (TTM)-2.05%
52-Week Low$7.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.39
4.39
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
STOKStoke Therapeutics, Inc. Common Stock | 11.95x | 404.50% | — | — | $36.46 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Stoke Therapeutics develops antisense oligonucleotides (ASOs) to treat genetic diseases through its proprietary TANGO platform, which restores protein expression in haploinsufficiency disorders. The company's lead candidate, zorevunersen, has demonstrated potential for disease modification in Dravet syndrome patients. Its pipeline focuses on mutation-agnostic treatments for rare genetic disorders affecting the central nervous system and eye.